A phase II study of erlotinib for patients with pretreated non-small cell lung cancer with brain metastasis and sensitive EGFR mutations.
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000002861
- Lead Sponsor
- Shizuoka General Hospital Respiratory center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Not provided
Patients with at least one of the following conditions are ineligible 1) Patients with idiopathic pulmonary fibrosis, other interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, drug induced pulmonary damage 2)Patients with pleural effusion, ascites and/or pericardial effusion requiring drainage 3)Patients with infection requiring iv administration of antibiotics and/or antifungal agents 4)Patients who has received HER modulator medicine in the past 5)Patients unable to be treated with PO drugs 6) Clinically significant eye diseases such as severe dry eye, keratoconjunctivitis 7)Pregnant or breast feeding 8) Active synchronous malignancies 9) Uncontrolled diabetes mellitus 10)Other clinically significant complications 11)Patients judged as being in inappropriate condition for this study by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method